Cyclosporine reduces mortality from Covid-19, study says


A team of Spanish researchers has found evidence in a retrospective study that the cyclosporine drug could reduce mortality from covid-19, although clinical trials are still needed to demonstrate these results.

Specifically, scientists, who have analyzed the treatments of more than 600 patients with covid-19, have found that those who received cyclosporine – a drug currently used in transplant patients– were 81% less likely to die than patients who did not receive this treatment.

The results of this observation are published in the journal E Clinical Medicine of the group The Lancet and the study is led by the Quirónsalud Madrid University Hospital, together with the European University.

To reach their conclusions, they analyzed the treatments of more than 600 patients with covid-19 admitted to the hospital from March 10 to April 15.

“In our series, patients who received cyclosporine were 81% less likely to die than patients who did not receive this treatment,” he explains in a note. Daniel Carnevali, Head of the Internal Medicine Service of the Quirónsalud Madrid University Hospital and professor at the aforementioned university.

This expert recalls that the disease by coronavirus SARS-CoV-2 does not yet have a standard treatment.

During the first stage of the pandemic, he explains, “we used therapies on which we had a reasonable hope that they would have an effect, but without clinical trials to support them: antimalarials such as hydroxychloroquine, antivirals such as Lopinavir-ritonavir, antibiotics, corticosteroids were used. and drugs that act in the inflammatory phase of the disease such as tozilizumab and cyclosporine “.

Also read: Covid-19: Remdesivir, dexamethasone and other drugs used against the pandemic

“The most surprising finding of our study is that patients who received cyclosporine had a longer survival compared to those who had not taken it,” emphasizes this researcher, who nonetheless emphasizes that “the results must be taken with caution.”

In this sense, he argues: our study is retrospective, it is not a double-blind randomized study comparing drug to drug.

“What we have verified is that patients who have received cyclosporine are not essentially different from other patients, suffered from similar comorbidities, and yet their clinical outcome has been better. “

And he concludes: “We have found evidence that cyclosporine could be a promising drug. To confirm this hypothesis, a clinical trial would be necessary in which it could be randomized between patients taking cyclosporine or placebo.”

nrv


Source link by https://www.eluniversal.com.mx/ciencia-y-salud/la-ciclosporina-reduce-la-mortalidad-por-covid-19-asegura-estudio

*The article has been translated based on the content of Source link by https://www.eluniversal.com.mx/ciencia-y-salud/la-ciclosporina-reduce-la-mortalidad-por-covid-19-asegura-estudio
. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!

*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.

*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!

These were the details of the news Cyclosporine reduces mortality from Covid-19, study says for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at en24news and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

PREV Iran rules out nuclear deal meeting, says time not ‘suitable’
NEXT Trump, returning to political stage, flirts with 2024 run